The Laboratory Model Under Structural Pressure
The centralised laboratory has been the organisational backbone of clinical diagnostics for more than a century. The logic was compelling and durable: centralise expensive analytical instruments, trained laboratory scientists, and quality control infrastructure in a single facility, route patient samples to that facility for analysis, and distribute results back to clinicians and patients through established reporting systems. That model delivered reliable, high-throughput diagnostic testing at a cost per test that improving automation and economies of scale consistently reduced. It also introduced an unavoidable latency — the time between sample collection and result availability — that in many clinical contexts is the binding constraint on diagnostic utility. A patient in an emergency department, a clinician in a rural health post, a pharmacist providing an in-store health service: all are served poorly by a diagnostic paradigm built around batch processing at a centralised facility.
Point-of-care diagnostics — testing performed at or near the patient, with results available in minutes rather than hours or days — has been a defined market category for decades, primarily in blood glucose monitoring for diabetic patients and in rapid strep and influenza testing in primary care settings. The current structural shift is different in both scope and technological basis. The range of analytes measurable at the point of care has expanded dramatically through the application of microfluidics, lateral flow immunoassay technology, electrochemical biosensors, and miniaturised molecular amplification systems. Cardiac biomarkers including troponin and BNP, coagulation parameters, inflammatory markers including C-reactive protein and procalcitonin, and a growing panel of infectious disease targets are all now measurable at the point of care with analytical performance approaching that of laboratory reference methods.
The Technology Enablers Driving Category Expansion
The microfluidic lab-on-chip platform is the technology architecture that has enabled the most ambitious point-of-care diagnostic capabilities. By miniaturising the fluidic handling, reagent mixing, separation, and detection functions of laboratory instruments onto chip-scale platforms using microfabrication techniques borrowed from semiconductor manufacturing, lab-on-chip devices achieve analytical performance in a handheld or benchtop format that would have required substantial laboratory infrastructure a decade ago. Established commercial implementations include Abbott's i-STAT system and Siemens Healthineers' epoc system for critical care testing. Emerging platforms including Cepheid's GeneXpert and BioFire's FilmArray are extending lab-on-chip performance to nucleic acid amplification testing — historically the most technically demanding category of diagnostic testing — in formats operable by non-laboratory personnel in decentralised settings.
Artificial intelligence integration into point-of-care platforms is creating a further capability expansion. Image analysis AI applied to lateral flow immunoassay results replaces subjective visual interpretation with quantitative optical measurement, improving analytical sensitivity and reducing operator variability. AI-powered clinical decision support integrated with point-of-care result reporting provides context-specific interpretation guidance and differential diagnosis support at the time results are generated, increasing clinical utility for clinicians who may lack specialist background to optimally interpret results in complex clinical contexts. The combination of improved analytical performance and AI-enhanced interpretation is progressively reducing the clinical performance gap between point-of-care and laboratory diagnostics that historically justified the laboratory model on quality grounds.
Market Segments Where Displacement Is Most Advanced
The clinical segments where point-of-care displacement of centralised laboratory testing is most advanced are those where the time-to-result benefit of decentralised testing is greatest relative to the analytical performance requirement. Emergency and critical care medicine is the segment where point-of-care adoption is most well-established, because clinical decision-making in acute presentations — chest pain, sepsis, acute kidney injury, coagulopathy in trauma — is time-critical in ways that cannot be served by laboratory turnaround times measured in hours. The i-STAT and epoc platforms for critical care blood analysis, and rapid troponin testing systems for chest pain evaluation, have achieved widespread adoption in emergency departments globally and have demonstrably reduced time-to-treatment in acute cardiac presentations.
Infectious disease is the second segment of advanced displacement, driven by the COVID-19 pandemic's acceleration of rapid test adoption and by the sustained investment in decentralised infectious disease testing infrastructure that the pandemic prompted. Influenza, RSV, streptococcal pharyngitis, urinary tract infection, and sexually transmitted infection testing are all migrating toward point-of-care formats in primary care and pharmacy settings at rates that laboratory diagnostics companies are being forced to accommodate in their strategic planning. Primary care and community health settings represent the largest addressable market for further expansion, because the volume of diagnostic testing performed in these settings is larger than the emergency and critical care segment and the barriers to laboratory access are highest for the populations they serve.
Supply Chain and Commercial Implications
The structural shift toward point-of-care diagnostics is creating significant commercial pressure on established in-vitro diagnostics companies whose business models are built around centralised laboratory instrument placements and high-volume reagent consumable revenue. The laboratory diagnostics economics — capital-intensive instrument placement subsidised by long-term reagent supply contracts at high margins — are not directly replicable in the point-of-care model, where smaller devices placed in more numerous and more distributed locations require different commercial approaches, different field service models, and different customer relationships. Roche, Abbott, Siemens Healthineers, and Beckman Coulter have all made substantial investments in point-of-care diagnostic platforms to participate in the segment they are at risk of being displaced by, but their commercial infrastructure is optimised for the laboratory model that point-of-care is disrupting.
The supply chain for point-of-care diagnostics — encompassing microfluidic consumables, biosensor components, optical detection systems, and connectivity infrastructure — is more geographically fragmented and less consolidated than the laboratory reagent supply chain. The rapid scaling of point-of-care manufacturing capacity during the COVID-19 pandemic revealed both the agility advantages of the decentralised supply chain and its vulnerabilities in terms of component supply constraints, quality consistency at scale, and regulatory compliance infrastructure that was inadequate for the production volumes being demanded. The investment in point-of-care manufacturing capability that followed the pandemic is creating a supply chain infrastructure for decentralised diagnostics that is substantially more capable than what existed before 2020, and that is a necessary foundation for the next phase of the market's structural shift away from centralised laboratory testing.